🔹 Tarek Ben Ahmed presenting in the Poster Session on Prevention, Risk Reduction, and Genetics: One-year impact of a large-scale pilot multimodal personalized early #cancer detection and prevention program for individuals at high risk of cancer. @ascocancer.bsky.social #ASCO25 #ASCO

🔹 Gustave Roussy at #ASCO25 🔹 Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care. #BreastCancer #Survivorship #eHealth

🔹 Gustave Roussy at #ASCO25 🔹 Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social. Press release ⤵ #ASCO

🔹 Gustave Roussy at #ASCO25 🔹 Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵ @ascocancer.bsky.social

🔹 Gustave Rouss at ASCO 2025 🔹 Prof. Laurence Zitvogel presents microbiome session at #ASCO. @ascocancer.bsky.social

🔹 Gustave Roussy at #ASCO25 🔹 Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer. @ascocancer.bsky.social

🔹 Gustave Roussy à l'#ASCO25 🔹 Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵

🔹 Gustave Roussy at #ASCO25. 🔹 The Institute's experts have arrived on site. Follow them throughout the weekend. @ascocancer.bsky.social

🚀 #ASCO25 is on! Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social

New data in pancreatic #cancer! The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL. 👉 doi.org/10.1200/JCO-... #PancreaticCancer #OncoResearch #FOLFIRINOX

🚨Few days left! Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses. 🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research. ⬇

Researchers from the Crick, @ucl.ac.uk, @gr-research.bsky.social and @mskcancercenter.bsky.social have discovered that certain age-related genetic changes in the blood are associated with worse outcomes for cancer patients. www.crick.ac.uk/news/2025-04...

📢 Excited to launch Signadori Bio with Sofinnova Partners! Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵ #CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio

📰 New ERN-EuroBloodNet guidelines for adult Burkitt lymphoma now published in The Lancet Haematology. First EU-wide recommendations to harmonise diagnosis, risk-adapted treatment & prognosis. 🔗 doi.org/10.1016/S235... #Lymphoma #Haematology

📢 New publication from @gustaveroussy.fr researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢 Read the study: doi.org/10.1038/s430...

Congrats to Thomas Mercher @gustaveroussy.fr, Erika Brunet @institutimagine.bsky.social and all involved in this beautiful study just out in Blood ⤵️

NEW PUBLICATION! Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia. A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more. doi.org/10.1182/bloo...

📣 We are excited to announce the first scientific day on liquid biopsy, organized by @gustaveroussy.fr and the IHU PRISM, taking place on June 11, 2025, in Paris! 🧬🔬 🔗 More information & registration:

📰 Low-dose gut radiation enhances immunotherapy. New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment. #Immunotherapy #Oncology #PDL1

📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses. Communiqué de presse ⤵

📰 “De-escalation in Lung Cancer Treatment: Are We Ready?” A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.    🔗 ascopubs.org/doi/full/10....

📰 Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine. 🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans. More informations 👇

Congrès IFODS 2025 🚀 📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵

📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de Gustave Roussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique. ⤵⤵⤵

🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀 📅 June 17-18, 2025 📍 Paris, France 🌍 Bringing together top researchers, clinicians, and industry leaders 🔗 Register now and be part of the conversation: www.aiinoncology.com

📰 We are thrilled to share our paper in Nature Reviews Cancer: "The Evolutionary Theory of Cancer: Challenges and Potential Solutions" by Lucie Laplane (Gustave Roussy) and Carlo Maley (Arizona State University). Read the full paper here ⤵ www.nature.com/articles/s41...